JP7402545B2 - 無針血管アクセスコネクタのための密封及びクリーンシング装置 - Google Patents
無針血管アクセスコネクタのための密封及びクリーンシング装置 Download PDFInfo
- Publication number
- JP7402545B2 JP7402545B2 JP2021549198A JP2021549198A JP7402545B2 JP 7402545 B2 JP7402545 B2 JP 7402545B2 JP 2021549198 A JP2021549198 A JP 2021549198A JP 2021549198 A JP2021549198 A JP 2021549198A JP 7402545 B2 JP7402545 B2 JP 7402545B2
- Authority
- JP
- Japan
- Prior art keywords
- cleaning
- sealing
- outer housing
- matrix
- housing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004140 cleaning Methods 0.000 title claims description 421
- 238000007789 sealing Methods 0.000 title claims description 173
- 230000002792 vascular Effects 0.000 title claims description 26
- 239000011159 matrix material Substances 0.000 claims description 239
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 72
- 239000003153 chemical reaction reagent Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 23
- 230000002262 irrigation Effects 0.000 claims description 21
- 238000003973 irrigation Methods 0.000 claims description 21
- 239000000645 desinfectant Substances 0.000 claims description 17
- 230000014759 maintenance of location Effects 0.000 claims description 14
- 238000011010 flushing procedure Methods 0.000 claims 1
- 239000006226 wash reagent Substances 0.000 claims 1
- 239000000463 material Substances 0.000 description 48
- 230000000295 complement effect Effects 0.000 description 43
- 238000004519 manufacturing process Methods 0.000 description 36
- 239000012530 fluid Substances 0.000 description 24
- 238000004659 sterilization and disinfection Methods 0.000 description 21
- 244000005700 microbiome Species 0.000 description 19
- -1 plasma Substances 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 239000006260 foam Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000011109 contamination Methods 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 230000006835 compression Effects 0.000 description 11
- 238000007906 compression Methods 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 229920003023 plastic Polymers 0.000 description 11
- 239000004033 plastic Substances 0.000 description 11
- 229920000742 Cotton Polymers 0.000 description 9
- 206010040047 Sepsis Diseases 0.000 description 9
- 208000037815 bloodstream infection Diseases 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 229910052709 silver Inorganic materials 0.000 description 9
- 239000004332 silver Substances 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 6
- 206010029803 Nosocomial infection Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241000894007 species Species 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 229960003260 chlorhexidine Drugs 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001746 injection moulding Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 229920002994 synthetic fiber Polymers 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 3
- 229940071536 silver acetate Drugs 0.000 description 3
- 239000002993 sponge (artificial) Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000008867 communication pathway Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 239000006261 foam material Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- NVLHGZIXTRYOKT-UHFFFAOYSA-N 1-chloro-2,3-dimethylbenzene Chemical group CC1=CC=CC(Cl)=C1C NVLHGZIXTRYOKT-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- YIROYDNZEPTFOL-UHFFFAOYSA-N 5,5-Dimethylhydantoin Chemical compound CC1(C)NC(=O)NC1=O YIROYDNZEPTFOL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- AKGWUHIOEVNNPC-LURJTMIESA-N Arg-OEt Chemical compound CCOC(=O)[C@@H](N)CCCNC(N)=N AKGWUHIOEVNNPC-LURJTMIESA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- UILOTUUZKGTYFQ-UHFFFAOYSA-N Mafenide acetate Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000015291 Pipra Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010082714 Silver Proteins Proteins 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229950006334 apramycin Drugs 0.000 description 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- LJBSAUIFGPSHCN-UHFFFAOYSA-N butenafine hydrochloride Chemical compound [Cl-].C=1C=CC2=CC=CC=C2C=1C[NH+](C)CC1=CC=C(C(C)(C)C)C=C1 LJBSAUIFGPSHCN-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000005108 dry cleaning Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 229960002721 mafenide acetate Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920005554 polynitrile Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229940071575 silver citrate Drugs 0.000 description 1
- YSVXTGDPTJIEIX-UHFFFAOYSA-M silver iodate Chemical compound [Ag+].[O-]I(=O)=O YSVXTGDPTJIEIX-UHFFFAOYSA-M 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 1
- MNMYRUHURLPFQW-UHFFFAOYSA-M silver;dodecanoate Chemical compound [Ag+].CCCCCCCCCCCC([O-])=O MNMYRUHURLPFQW-UHFFFAOYSA-M 0.000 description 1
- LTYHQUJGIQUHMS-UHFFFAOYSA-M silver;hexadecanoate Chemical compound [Ag+].CCCCCCCCCCCCCCCC([O-])=O LTYHQUJGIQUHMS-UHFFFAOYSA-M 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/20—Closure caps or plugs for connectors or open ends of tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M39/16—Tube connectors; Tube couplings having provision for disinfection or sterilisation
- A61M39/162—Tube connectors; Tube couplings having provision for disinfection or sterilisation with antiseptic agent incorporated within the connector
Description
以下の説明は、本発明を理解するのに有用であり得る情報を含む。そのような情報は、いずれも、現在特許請求されている発明に先行技術であるか、または関連していること、または具体的にまたは暗黙に参照されている記載が先行技術であることを容認するものではない。
医療分野、特に、患者への流体の注入または患者からの流体の吸引の分野において、ルアーアクセス装置、例えば、無針弁コネクタ(NC)などの医療装置の汚染されている可能性のある表面からの患者への病原体の伝播を防止する必要性が依然として存在する。病原体には、細菌、真菌、ウイルスなどの微生物が含まれ、その微生物が患者に伝播すると、生命を脅かす可能性のある感染症を引き起こすことがある。医療現場に特化して、「院内感染」という用語は、病院または病院のような状況に由来する、または発生する感染を意味する。米国では、院内感染は全ての急性期入院の少なくとも5%で発生すると推定されている。推定発生率は年間200万例以上であり、重大な罹患率、死亡率、および経費をもたらす。実際、院内感染はあらゆる入院患者の死亡率と罹患率のリスクの2倍以上と見積もられており、米国だけでも年間約100,000人が死亡する可能性が高い。患者の血流中への汚染微生物の伝播のための一般的な部位は、ルアーアクセス装置、バイアル、無針(または無針)弁、ならびに容器、チューブ、およびカテーテルの注入口などの医療装置上に見出される。患者におけるこのような感染症の発生率は増加しており、感染管理開業医(ICP)は、しばしばこのような感染症の主要な感染源として、部位の不適切な洗浄を挙げている。
本発明を詳細に説明する前に、本発明の文脈で使用されるいくつかの用語を定義する。これらの用語に加えて、他の用語は、必要に応じて、本明細書の他の箇所で定義される。本明細書中で特に明確に定義されない限り、本明細書中で使用される技術用語は、それらの技術的に認識された意味を有する。
以下の詳細な説明では、その一部を形成する添付の図面(図1~10)を参照する。図において、同様の記号は、文脈が別段の指示をしない限り、典型的には同様の構成要素を識別する。詳細な説明、図面、および特許請求の範囲に記載される例示的な実施形態は、限定することを意味しない。本明細書に提示される主題の精神または範囲から逸脱することなく、他の実施形態を利用することができ、他の変化を行うことができる。
本発明の特定の好ましい代表的な実施形態をさらに例示し、説明するために、リーダは、本発明の密封および洗浄装置の様々な特に好ましい実施形態を例示する添付の図面、図1~10を対象とする。これらの好ましい代表的な実施形態について以下に説明する。
Claims (14)
- 無針脈管アクセスコネクタのねじ切りされた弁部分用の密封および洗浄装置であって、
外側筐体と、該外側筐体内で回転可能に配置される内側筐体と、前記外側筐体に取り付けられた圧縮可能な洗浄マトリックスを備え、
前記内側筐体は、無針脈管アクセスコネクタの前記ねじ切りされた弁部分に当該密封および洗浄装置をねじ込み、かつ、前記弁部分から当該密封および洗浄装置のねじを緩めることができるように構成されて互いに反対側に設けられる第1開口と第2開口を有する中心ボアの境界を構成する側壁を備え、当該密封および洗浄装置が前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分へねじ込められるとき、前記外側筐体に取り付けられた圧縮可能な洗浄マトリックスが前記内側筐体内部に入り込んで前記中心ボアへ突出すことで前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分のバルブ面と接触することを可能にし、
前記外側筐体は、内部で前記内側筐体が回転可能に配置されるキャビティを備えて、(A)前記内側筐体を保持し、(B)前記内側筐体を係合及び係合解除することで、前記外側筐体が前記内側筐体に係合されないときには、(i)前記内側筐体を保持して、ユーザーによって時計回りと反時計回りの両方向において少なくとも360°前記外側筐体に前記内側筐体から独立して回転することが可能なように構成され、
前記圧縮可能な洗浄マトリックスは、前記外側筐体の前記キャビティへ突出し、前記外側筐体と共に回転して、液体消毒剤で含浸される、
密封および洗浄装置。 - 請求項1に記載の密封および洗浄装置であって、外部環境から前記内側筐体の前記キャビティを封止する取り外し可能な封止体をさらに備える、密封および洗浄装置。
- 請求項1に記載の密封および洗浄装置であって、前記液体消毒剤は、イソプロピルアルコールを含む、密封および洗浄装置。
- 請求項1に記載の密封および洗浄装置であって、前記外側筐体は複数の垂直リッジを有する外側表面を含む、密封および洗浄装置。
- 無針脈管アクセスコネクタを洗浄する方法であって、(a) 請求項1に記載の密封および洗浄装置へ前記無針脈管アクセスコネクタのねじ切りされた弁部分を接続することで、前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分の1つ以上の表面が前記圧縮可能な洗浄マトリックスと係合して当該密封および洗浄装置の前記圧縮可能な洗浄マトリックスの少なくとも一部を圧縮する段階と、(b) 当該密封および洗浄装置の前記外側筐体を前記内側筐体に対して回転可能にして、前記外側筐体を前記内側筐体及び前記無針脈管アクセスコネクタに対して回転させることで、当該密封および洗浄装置の前記圧縮可能な洗浄マトリックスによって接続される前記無針脈管アクセスコネクタの1つ以上の表面を洗浄する段階と、
を有する方法。 - 請求項5に記載の方法であって、洗浄後に当該密封および洗浄装置へ接続される前記無針脈管アクセスコネクタを外すことで前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分を密封する段階をさらに有する、方法。
- 請求項1に記載の密封および洗浄装置であって、前記液体消毒剤は、70%イソプロピルアルコール溶液を含む、密封および洗浄装置。
- 請求項1~4,7のいずれか一項に記載の無針脈管アクセスコネクタのねじ切りされた弁部分用の密封および洗浄装置であって、
前記内側筐体はさらに、外側筐体係合領域と、内側筐体保持領域と、外側筐体保持領域を備え、
前記無針脈管アクセスコネクタの前記ねじ切された弁部分と解放可能に係合するように構成された1つ以上のねじ係合タブまたはねじ山が下端開口に近接し、かつ、前記中心ボア上に配置され、
前記外側筐体係合領域は、当該密封および洗浄装置の外側筐体の解放可能な機械的係合を供するように構成され、
前記外側筐体保持領域は、前記外側筐体係合領域が係合されないときに、前記外側筐体のキャビティ内での前記内側筐体を保持し、及び、前記外側筐体の前記内側筐体に対する少なくとも360°の回転を時計回り方向と反時計回り方向の両方で可能にするように構成され、
前記外側筐体は、外壁と上壁とによって形成されたキャビティと、同心のマトリックスウェルと、前記内側筐体を前記キャビティ内に解放可能に係合及び保持するように構成された少なくとも1つの内側筐体係合構造および少なくとも1つの内側筐体保持構造とを備え、
前記少なくとも1つの内側筐体係合構造が前記内側筐体と係合すると、前記内側筐体と前記外側筐体は、一体とって回転することができ、前記外側筐体の前記少なくとも1つの内側筐体係合構造が前記内側筐体から係合しないと、前記外側筐体は、前記内側筐体に対して回転することが可能で、
前記圧縮可能な洗浄マトリックスは、内部に配置され、前記外側筐体のマトリックスウェルに固定された液体洗浄試薬を含み、
前記圧縮可能な洗浄マトリックスは、当該密封および洗浄装置が前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分に固定され、かつ、前記外側筐体および前記圧縮可能な洗浄マトリックスが前記内側筐体に対して回転されるときに、前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分の1つ以上の表面に接触及び洗浄するように構成される、
密封および洗浄装置。 - 請求項8に記載の密封および洗浄装置であって、外部環境から当該密封および洗浄装置のキャビティを封止する取り外し可能な封止体をさらに備える、密封および洗浄装置。
- 請求項8に記載の密封および洗浄装置であって、前記液体洗浄試薬はイソプロピルアルコールを含む、密封および洗浄装置。
- 請求項8に記載の密封および洗浄装置であって、前記外側筐体は複数の垂直リッジを有する外側表面を含む、密封および洗浄装置。
- 無針脈管アクセスコネクタを洗浄する方法であって、(a) 請求項7に記載の密封および洗浄装置へ前記無針脈管アクセスコネクタのねじ切りされた弁部分を接続することで、前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分の1つ以上の表面が当該密封および洗浄装置の前記圧縮可能な洗浄マトリックスと係合して前記圧縮可能な洗浄マトリックスの少なくとも一部を圧縮する段階と、(b) 当該密封および洗浄装置の前記外側筐体を前記内側筐体に対して回転可能にして、前記外側筐体を前記内側筐体及び前記無針脈管アクセスコネクタに対して回転させることで、当該密封および洗浄装置の前記圧縮可能な洗浄マトリックスによって接続される前記無針脈管アクセスコネクタの前記1つ以上の表面を洗浄する段階と、
を有する方法。 - 請求項12に記載の方法であって、洗浄後に当該密封および洗浄装置へ接続される前記無針脈管アクセスコネクタを外すことで前記無針脈管アクセスコネクタの前記ねじ切りされた弁部分を密封する段階をさらに有する、方法。
- 請求項8に記載の密封および洗浄装置であって、前記液体洗浄試薬は、70%イソプロピルアルコール溶液を含む、密封および洗浄装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023204751A JP2024037783A (ja) | 2019-02-19 | 2023-12-04 | 無針血管アクセスコネクタのための密封及びクリーンシング装置 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962807239P | 2019-02-19 | 2019-02-19 | |
US62/807,239 | 2019-02-19 | ||
PCT/US2020/018924 WO2020172346A1 (en) | 2019-02-19 | 2020-02-19 | Capping and cleansing devices for needlefree vascular access connectors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023204751A Division JP2024037783A (ja) | 2019-02-19 | 2023-12-04 | 無針血管アクセスコネクタのための密封及びクリーンシング装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022520491A JP2022520491A (ja) | 2022-03-30 |
JP7402545B2 true JP7402545B2 (ja) | 2023-12-21 |
Family
ID=72144159
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021549198A Active JP7402545B2 (ja) | 2019-02-19 | 2020-02-19 | 無針血管アクセスコネクタのための密封及びクリーンシング装置 |
JP2023204751A Pending JP2024037783A (ja) | 2019-02-19 | 2023-12-04 | 無針血管アクセスコネクタのための密封及びクリーンシング装置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023204751A Pending JP2024037783A (ja) | 2019-02-19 | 2023-12-04 | 無針血管アクセスコネクタのための密封及びクリーンシング装置 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3927415A4 (ja) |
JP (2) | JP7402545B2 (ja) |
CN (1) | CN114401765A (ja) |
AU (2) | AU2020225386B2 (ja) |
CA (1) | CA3130950A1 (ja) |
MA (1) | MA55036A (ja) |
WO (1) | WO2020172346A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011798A1 (ja) | 2003-07-31 | 2005-02-10 | Jms Co., Ltd. | 医療用コネクタシステム |
WO2008100950A2 (en) | 2007-02-12 | 2008-08-21 | Ivera Medical Corporation | Medical implement cleaning device |
US20120111368A1 (en) | 2010-10-20 | 2012-05-10 | Fresenius Kabi Deutschland Gmbh | Protective cap for a connector |
JP2017506124A (ja) | 2014-02-20 | 2017-03-02 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 抗菌保護を提供するためのivアクセスポートキャップ |
US20180256879A1 (en) | 2017-03-10 | 2018-09-13 | Turnstone Technologies, LLC | Device port cleaner |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5153949Y2 (ja) * | 1971-12-25 | 1976-12-23 | ||
US6050978A (en) * | 1997-05-09 | 2000-04-18 | Becton Dickinson And Company | Needleless valve connector |
US7198611B2 (en) * | 2002-02-11 | 2007-04-03 | Baxter International Inc. | Dialysis connector and cap having an integral disinfectant |
US20110184382A1 (en) * | 2009-08-20 | 2011-07-28 | Cady Timothy B | Multi-purpose articles for sanitizing and capping luer access valves |
US10166381B2 (en) * | 2011-05-23 | 2019-01-01 | Excelsior Medical Corporation | Antiseptic cap |
CN106421848B (zh) * | 2016-10-14 | 2022-09-23 | 刘浩浩 | 一次性使用无针输液接头消毒装置 |
CN106861033B (zh) * | 2017-03-28 | 2020-04-03 | 文森特.雷斯科维奇 | 一种抗菌帽及其生产方法 |
US20190070404A1 (en) * | 2017-08-08 | 2019-03-07 | CleanSite Medical, Inc. | Luer access device capping and cleansing devices |
-
2020
- 2020-02-19 WO PCT/US2020/018924 patent/WO2020172346A1/en unknown
- 2020-02-19 JP JP2021549198A patent/JP7402545B2/ja active Active
- 2020-02-19 AU AU2020225386A patent/AU2020225386B2/en active Active
- 2020-02-19 CA CA3130950A patent/CA3130950A1/en active Pending
- 2020-02-19 MA MA055036A patent/MA55036A/fr unknown
- 2020-02-19 CN CN202080029883.2A patent/CN114401765A/zh active Pending
- 2020-02-19 EP EP20759166.0A patent/EP3927415A4/en not_active Withdrawn
-
2022
- 2022-06-30 AU AU2022204713A patent/AU2022204713A1/en not_active Abandoned
-
2023
- 2023-12-04 JP JP2023204751A patent/JP2024037783A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011798A1 (ja) | 2003-07-31 | 2005-02-10 | Jms Co., Ltd. | 医療用コネクタシステム |
WO2008100950A2 (en) | 2007-02-12 | 2008-08-21 | Ivera Medical Corporation | Medical implement cleaning device |
US20120111368A1 (en) | 2010-10-20 | 2012-05-10 | Fresenius Kabi Deutschland Gmbh | Protective cap for a connector |
JP2017506124A (ja) | 2014-02-20 | 2017-03-02 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 抗菌保護を提供するためのivアクセスポートキャップ |
US20180256879A1 (en) | 2017-03-10 | 2018-09-13 | Turnstone Technologies, LLC | Device port cleaner |
Also Published As
Publication number | Publication date |
---|---|
CN114401765A (zh) | 2022-04-26 |
EP3927415A4 (en) | 2022-11-02 |
JP2024037783A (ja) | 2024-03-19 |
WO2020172346A1 (en) | 2020-08-27 |
AU2020225386B2 (en) | 2022-03-10 |
AU2022204713A1 (en) | 2022-07-21 |
EP3927415A1 (en) | 2021-12-29 |
AU2020225386A1 (en) | 2021-10-14 |
CA3130950A1 (en) | 2020-08-27 |
MA55036A (fr) | 2021-12-29 |
JP2022520491A (ja) | 2022-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11065431B2 (en) | Capping and cleansing devices for needlefree vascular access connectors | |
US8999073B2 (en) | Medical implement cleaning device | |
US11027112B2 (en) | Apparatuses for cleaning catheter ports | |
EP2938374B1 (en) | Sintered porous polymeric caps and vents for components of medical devices | |
US20090041619A1 (en) | Devices for sanitizing medical fittings | |
US20110184382A1 (en) | Multi-purpose articles for sanitizing and capping luer access valves | |
US20210346672A1 (en) | Capping and cleansing devices for threaded vascular access connectors | |
CN106421848B (zh) | 一次性使用无针输液接头消毒装置 | |
JP2013509274A (ja) | 消毒キャップ、システムおよび関連方法 | |
US20100296968A1 (en) | Sanitizing devices for needleless medical fittings | |
KR20120067343A (ko) | 암 루어 연결기용 소독 수단을 구비한 숫 루어 연결기용 캡 | |
US20190070404A1 (en) | Luer access device capping and cleansing devices | |
JP7402545B2 (ja) | 無針血管アクセスコネクタのための密封及びクリーンシング装置 | |
US20220387776A1 (en) | Sanitizing articles for luer access devices | |
CN219783534U (zh) | 一种用于连接到母医疗连接器的消毒装置 | |
US20190217077A1 (en) | Devices and methods to maintain clean surfaces on medical connectors | |
JP2022540206A (ja) | オスおよびメスルアーコネクタ用の消毒スクラブ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211025 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211025 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20211025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220524 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220823 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230518 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230921 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231102 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7402545 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |